Intensity Therapeutics, Inc. (INTS)

USD 1.91

(-4.5%)

Market Cap (In USD)

28.85 Million

Revenue (In USD)

-

Net Income (In USD)

-10.53 Million

Avg. Volume

11.6 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.77-8.79
PE
-
EPS
-
Beta Value
5.133217
ISIN
US45828J1034
CUSIP
CIK
1567264
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Lewis H. Bender M.A., M.B.A., M.S.
Employee Count
-
Website
https://www.intensitytherapeutics.com
Ipo Date
2023-06-30
Details
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.